Andrew Tutt

Andrew Tutt at King's College London led the OlympiA trial establishing adjuvant olaparib as standard of care for BRCA-mutated high-risk early breast cancer, representing a landmark clinical translation of synthetic lethality. He was among the first to demonstrate clinical activity of olaparib in BRCA1/2-mutated breast cancer in early-phase studies. His research addresses neoadjuvant PARP inhibitor therapy, residual disease management, and the long-term implications of synthetic lethality-based adjuvant treatment. He leads breast cancer research at the Breast Cancer Now Toby Robins Research Centre.